Oxford Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Oxford Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-111,706	Closed	-$659K	–	1475
2019 Q4	$659K	Buy	111,706 +45,120	+68%	+$245K	0.02%	1091
2019 Q3	$353K	Sell	66,586 -28,078	-30%	-$186K	0.01%	1406
2019 Q2	$729K	Buy	94,664 +15,101	+19%	+$230K	0.02%	1117
2019 Q1	$1.58M	Buy	79,563 +70,691	+797%	+$1.23M	0.03%	699
2018 Q4	$117K	Buy	+8,872	New	+$177K	﹤0.01%	1634
2016 Q3	–	Sell	-57,387	Closed	-$3.25M	–	884
2016 Q2	$3.25M	Buy	+57,387	New	+$3.49M	0.11%	252

Other funds holding KDNY

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Oxford Asset Management's KDNY Position: Q1 2020 in Review

Oxford Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2020, closing a stake of 111,706 shares — an estimated $659K sold.

Oxford Asset Management first reported a position in KDNY in Q2 2016 and held it in 6 quarters. The position peaked at $3.25M in Q2 2016. 82 funds tracked by Wall St. Rank hold KDNY as of Q1 2020.

Oxford Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 111,706 Chinook Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $659K.
Oxford Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2016 and held it in 6 quarters.
Oxford Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $3.25M in Q2 2016.
82 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.